Tegoprazan (K-CAB) SKKUSOM 이준행
|
|
- Rudolph Craig
- 5 years ago
- Views:
Transcription
1 Tegoprazan (K-CAB) SKKUSOM 이준행
2 P-CAB (Tegoprazan, K-CAB TM ) 국내제30호신약 (code명: RQ-4, CJ-12420) Potassium Competitive Acid Blocker
3 위산과위산분비억제제 성균관대학교의과대학삼성서울병원소화기내과이준행
4 위산분비억제제개발의역사 H 2 RA Cimetidine, Ranitidine, Famotidine, Nizatidine, Roxatidine 1 st PPI Omeprazole, Lansoprazole, Pantoprazole 2 nd PPI Rabeprazole, Esomeprazole, Dexlansoprazole, Ilaprazole P-CAB Revaprazan, Vonoprazan, Tegoprazan (K-CAB)
5 새롭고강력한위산분비억제제에대하여어떤점을고려해야할것인가? 약효측면에서기존약제와무엇이다른가? 얼마나새롭고얼마나강력한가? 안전한가? 장기사용은가능한가? 고령, 신질환, 간 질환에서용량조절이필요한가? 편리한가? 약물복용시점, On demand therapy, 야 간증상, 유전자형에따른차이 또다른새로운특장점은무엇인가? MMC
6 오늘의 topic 위산과위산분비억제제 PPI vs tegoprazan Safety issues GERD에서 tegoprazan의역할 결론 : 새롭고강력한위산분비억제제 tegoprazan의다양한잠재적적응증
7 PPI vs Tegoprazan 성균관대학교의과대학삼성서울병원소화기내과이준행
8 PPIs Conversion to a reactive form Irreversible binding to the external surface of acid pump Need to stimulate proton pump P-CAB Directly binds to K+ Binding domain at resting and stimulated state Reversible binding No need to stimulate proton pump
9 어떤약의 onset 이빠를까요? Prodrug Conversion 후작용 Active form 처음부터바로작용
10 Reversible, competitive 란 in vitro 의현상일뿐입니다. 중요한것은 in vivo!
11 분류 P-CABs PPIs Drug Tegoprazan Revaprazan Vonoprazan Esomeprazole Dexlansoprazole Rabeprazole Chemical Structure In vivo 반감기 : 4-6 시간 - PPI 의반감기가보통 1-2 시간임에비하여 tegoprazan 의반감기는매우길다. Formula (MW) C 20 H 19 F 2 N 3 O 3 (387.38) C 22 H 23 FN 4 (362.44) C 17 H 16 FN 3 O 3 SC 4 H 4 O 4 (461.46) C 17 H 19 N 3 O 3 S (345.41) C 16 H 14 F 3 N 3 O 2 S ( ) C 18 H 21 N 3 O 3 S ( ) Derivatives Benzimidazole Carboxamide Pyrimidine Sulfonyl Pyrrole Sulfinyl Benzimidazole Chemical Name (S)-(-)-4-[5, 7-Difluoro-3, 4- dihydro-2h-chromen-4- yl)oxy]-n,n,2-trimethyl-1hbenzimidazole-6-carboxamide N-(4-fluorophenyl)-4,5- dimethyl-6-[(1rs)-1-methyl- 3,4-dihydroisoquinolin-2(1H)- yl]pyrimidin-2-amine 1-[5-(2-Fluorophenyl)-1- [(pyridin-3-yl)sulfonyl]-1hpyrrol-3-yl]-nmethylmethanamine (S)-5-Methoxy-2-[(4-methoxy- 3,5-dimethylpyridin-2- yl)methylsulfinyl]-3hbenzimidazole (R)-(+)2-([3-methyl-4- (2,2,2- trifluoroethoxy)pyridin-2- yl]methylsulfinyl)-1hbenzo[d]imidazole (RS)-2-([4-(3-methoxypropoxy)- 3-methylpyridin-2- yl]methylsulfinyl)-1hbenzo[d]imidazole pka T max * 1.25h ( h) 1.4~2.2h 1.5h (0.75~3 h) 1.6h 4~5h 3.5h Half life* 3.7~7.1h 14.8~26h 6.1~7h 1~1.5h 1~2h 1~1.5h Indications NDA (EE, NERD), P3 (GU, HP) GU, DU EE, GU,DU, HP EE, NERD, GU,DU, HP EE, NERD EE, NERD, GU, DU, HP * Phase 1 clinical study report/fda Label (Healthy subjects, Multiple dosing) ** EE: Erosive Esophagitis, NERD: Non-Erosive Reflux Disease, GU: Gastric Ulcer, DU: Duodenal Ulcer, HP: eradication of Helicobacter pylori.
12 Radioactivity (ng eq/mg) In vivo: 위조직농도가오래유지됨 Radioactivity of 14 C-tegoprazan in SD rats 10,000 7,500 5,000 At 0.5hr 2, Time (hr) Plasma Stomach At 8hr Ref. Clinical study report of [CJ_APA_101] study, KDDW 2017, P-UG-077, 078
13 More stable in canaliculi Akazawa. Therap Adv Gastroenterol. 2016;9:845-52
14 Fast, strong and long Andersson. Pharmacol Ther. 2005;108:
15 Benefits of K-CAB compared to PPI More potent acid suppression More rapid acid inhibition Better NAB control Less dependent on CYP2C19 No food effect Optimal for H. pylori eradication
16 1. More potent acid suppression Shin et al. KDDW 2017
17 2. More rapid acid inhibition Day 1. Fast onset (within 0.5~1h ) Day 7. Fast onset (within 0.5~1h ) Faster onset of acid-inhibitory effect (Time to ph 4) Greater acid-inhibitory effect in H. pylori (-) (Mean % time of ph 4) Day 1 Day 7 TEGOPRAZAN 50 mg Within 1 hour Within 1 hour TEGOPRAZAN 50 mg Day % Day % Ref. Clinical study report of [CJ_APA_108] study
18 Intragastric ph 3. NAB control Nocturnal Acid Breakthrough (NAB): >1 hr with ph<4 Does not necessarily denote a temporal relationship with symptom Can deteriorate symptom and progress of GERD PPIs can t control NAB properly due to MOA & properties NAB control of Tegoprazan Nocturnal Acid Breakthrough (NAB) vs. Tegoprazan: NAB control (morning dose) PPI PPI :00~4:00 am Time after dosing (hr) at Day 7 Ref. Modified illustration from Am J Gastroenterol 1998; 93: 763
19 4. Less dependent on CYP2C19 PPIs are strong inhibitors of CYP2C19. Individual variation by CYP2C19 polymorphism. Drug-drug interaction especially for clopidogrel. Dominant pathway of tegoprazan is CYP3A4 (75%).
20 Individual variation Adachi. Aliment Pharmacol Ther 2000;14:1259
21 Tegoprazan metabolic pathway - 75% by CYP3A K-CAB conference ( 신재국 )
22 5. No food effect No food effect on systemic exposures (AUC) Tegoprazan 200 mg Esomeprazole 40 mg* - 9.8% % No food effect on PD Ref. Br. J. Clin. Pharmacol 64: ) Arithmetic Mean Ref. Clinical study report of [CJ_APA_102] study
23 Intragastric ph 6. > ph 6: Tegoprazan bid > PPI bid - Optimal for H. pylori eradication Day 7 Mean % time of > ph % % Tegoprazan 50 mg, BID Pantoprazole 40 mg, BID Time (hr) Clinical study report of [CJ_APA_107] study
24 강력한산분비억제가필요한이유 H. pylori is more likely in a non-replicative state when gastric ph is low (ph 3 6). By raising ph, bacteria enter the replicative state and become susceptible to amoxicillin and clarithromycin. Increase the chemical stability of amoxicillin and clarithromycin in gastric juice, thus preventing the antimicrobials, which are fragile at lower ph levels, from degradation Malfertheiner. Gut 2016, Murakami. Gut 2016
25 두개의 3 상연구가진행되고있습니다. CJ_APA_306 CJ_APA_307
26
27 [CJ_APA_306] [CJ_APA_307] 등록률 350 명 /350 명 (100%) 138 명 /284 명 (48.6%) 선정 제외기준 H. pylori 진단방법 H. pylori 양성인자상부위장관내시경검사상다음의어느하나에해당하는자 - 소화성궤양 ( 위궤양또는십이지장궤양 ) - 반흔기상태의위궤양또는십이지장궤양 - 위궤양또는십이지장궤양기왕력이있었던자 - 만성위축성위염 (chronic atrophic gastritis) UBT( 필수 ) & CLO, 조직검사, 혈청검사, 대변항원검사중택 1 UBT(+) & 추가검사 (+) 양성으로판정 H. pylori 양성인자상부위장관내시경검사상다음의어느하나에해당하는자 - 소화성궤양 ( 위궤양또는십이지장궤양 ) - 저등급위 MALT 림프종 - EMR/ESD 치료후완전절제된조기위암환자로서제균치료가필요한경우 - 만성위축성위염 (chronic atrophic gastritis) UBT( 필수 ) & CLO, 조직검사중택 1 UBT(+) & 추가검사 (+) 양성으로판정 임상시험용의약품 투여방법 1 일 2 회, 7 일, 식후 1 일 2 회, 7 일, 식전 항생제감수성검사위전정부에서 2 개 위전정부및체부대만에서각각 1 개씩 PUD 치료 Active, Healed Stage GU, DU: 라니티딘 (H2-RA) 28 일처방 Active stage GU: 판토프라졸 (PPI) 28 일처방 DU: 판토프라졸 (PPI) 14 일처방
28 Safety issues 성균관대학교의과대학삼성서울병원소화기내과이준행
29 강력한위산분비억제의영향을주시해야 Tegoprazan?
30 현장에서걱정하는부분은? Tegoprazan launching symposium (Seoul)
31 간독성등으로개발이중단된약제들 - Chemocal class effect of imidazopyridine 기존개발진행중에중단되었던 P-CAB 중에일 부물질들이공통적으로가지고있던구조가 "imidazopyridine" 으로서 imidazopyridine 이간 독성을유발하는 chemical class effect 를갖고 있음
32 PPI 는모두유사한모양이지만 P-CAB 은서로다른구조식을가지고있음 분류 P-CABs PPIs Drug Tegoprazan Revaprazan Vonoprazan Esomeprazole Dexlansoprazole Rabeprazole Chemical Structure Formula (MW) C 20 H 19 F 2 N 3 O 3 (387.38) C 22 H 23 FN 4 (362.44) C 17 H 16 FN 3 O 3 SC 4 H 4 O 4 (461.46) C 17 H 19 N 3 O 3 S (345.41) C 16 H 14 F 3 N 3 O 2 S ( ) C 18 H 21 N 3 O 3 S ( ) Derivatives Benzimidazole Carboxamide Pyrimidine Sulfonyl Pyrrole Sulfinyl Benzimidazole Chemical Name (S)-(-)-4-[5, 7-Difluoro-3, 4- dihydro-2h-chromen-4- yl)oxy]-n,n,2-trimethyl-1hbenzimidazole-6-carboxamide N-(4-fluorophenyl)-4,5- dimethyl-6-[(1rs)-1-methyl- 3,4-dihydroisoquinolin-2(1H)- yl]pyrimidin-2-amine 1-[5-(2-Fluorophenyl)-1- [(pyridin-3-yl)sulfonyl]-1hpyrrol-3-yl]-nmethylmethanamine (S)-5-Methoxy-2-[(4-methoxy- 3,5-dimethylpyridin-2- yl)methylsulfinyl]-3hbenzimidazole (R)-(+)2-([3-methyl-4- (2,2,2- trifluoroethoxy)pyridin-2- yl]methylsulfinyl)-1hbenzo[d]imidazole (RS)-2-([4-(3-methoxypropoxy)- 3-methylpyridin-2- yl]methylsulfinyl)-1hbenzo[d]imidazole pka T max * 1.25h ( h) 1.4~2.2h 1.5h (0.75~3 h) 1.6h 4~5h 3.5h Half life* 3.7~7.1h 14.8~26h 6.1~7h 1~1.5h 1~2h 1~1.5h Indications NDA (EE, NERD), P3 (GU, HP) GU, DU EE, GU,DU, HP EE, NERD, GU,DU, HP EE, NERD EE, NERD, GU, DU, HP * Phase 1 clinical study report/fda Label (Healthy subjects, Multiple dosing) ** EE: Erosive Esophagitis, NERD: Non-Erosive Reflux Disease, GU: Gastric Ulcer, DU: Duodenal Ulcer, HP: eradication of Helicobacter pylori.
33 Tegoprazan safety profile
34 현재까지의임상연구에서유의한 heptotoxicity 를보이지않음
35 Vonoprazan 은 hypergastrinemia 가문제
36 Tegoprazan 은 lansoprazole 과유사한정도
37 Esomeprazole 과도유사한정도
38 GERD 에서 Tegoprazan 의역할 성균관대학교의과대학삼성서울병원소화기내과이준행
39 현장에서기대하는부분은? Tegoprazan launching symposium (Seoul)
40 현장에서기대하는부분은? Tegoprazan launching symposium (Seoul)
41 1. Erosive esophagitis 의초치료 성균관대학교의과대학삼성서울병원소화기내과이준행
42 % Total healed % Total heartburn free Erosive esophagitis 에서 PPI 가효과가좋다는것은누구나아는일입니다. Endoscopic healing Relief of symptoms 100 PPI 11.7%/wk 80 PPI 11.5%/wk H 2 RA 5.9%/wk H 2 RA 6.4%/wk 20 0 Placebo 2.9%/wk Weeks Weeks Chiba N et al. Gastroenterology 1997;112:1798
43 Tegoprazan (K-CAB) for ERD
44 Tegoprazan (K-CAB) for ERD
45 Tegoprazan (K-CAB) for ERD
46 Tegoprazan (K-CAB) for ERD
47 아마도위산분비억제능력이더좋기때문일것입니다. Shin et al. KDDW 2017
48 환자들이 PPI 를매우좋아했습니다. 그런데증상호전에는며칠이필요했습니다.
49 첫 dose 부터 onset 이아주빠른 tegoprazan 이라면어떤효과를보일까요? Shin et al. KDDW 2017
50 어쩌면증상개선은훨씬더빠르고장기적인 healing rate 는비슷하거나조금더나은정도일지모릅니다. Andersson. Pharmacol Ther. 2005;108:
51 GERD 초치료와유지요법의새로운전략 Mori and Suzuki. J Neurogastroenterol Motil 2019;25:6-14
52 2. Non-erosive reflux disease 성균관대학교의과대학삼성서울병원소화기내과이준행
53 Tegoprazan (K-CAB) for NERD
54 Tegoprazan (K-CAB) for GERD
55 3. Refractory GERD 성균관대학교의과대학삼성서울병원소화기내과이준행
56 Approaches to PPI-refractory GERD ph-impedance (= physiologic subtype) Empirical approach
57 ph monitoring ph-impedance Gastroenterol Clin N Am 2014;43:89 104
58 ph-impedance monitoring allows identification of subgroups of patients with symptoms that are suspected to be caused by reflux Gut 2014;63:
59 Approach based on phenotype Type Interpretation Personal approach 1 GERD 더강력한산분비억제제 2 3 정상범위산역류에대한과감각 산역류가있으나그와무관하게 globus 가있는경우 Pain modulator (amitryptiline) + ( 더강력한 ) 산분비억제제 Globus 때문에산분비억제제를쓸필요는없음. 산역류증상은산분비억제제로조절 4 GERD 아님 산분비억제제중단
60 Refractory GERD 의과거전략과신전략 Mori and Suzuki. J Neurogastroenterol Motil 2019;25:6-14
61 4. PPI 의 unmet needs 영역 성균관대학교의과대학삼성서울병원소화기내과이준행
62 Major unmet needs of PPIs Enteric coating & Alu/Alu package 6 1 Delayed onset High potential of DDI High individual variations 5 PPIs 2 Poor control of NAB Poor PD for H. pylori eradication 4 3 Poor compliance due to food effect
63 Tegoprazan 은 PPI 의 unmet needs 에대응하는여러좋은특징을가지고있음 Simple formulation & package 6 1 Fast onset Low potential of DDI Low individual variations 5 K-CAB Tegoprazan 2 On demand control of NAB Optimal PD for H.pylori eradication 4 3 No food effect
64 Breaktrough symptoms on PPI
65 Intragastric ph PPI 사용에도불구하고야간증상을가진환자에서사용할수있음 Dosing (IP) Meal Meal Meal Tegoprazan 50 mg Dexlansoprazole 60 mg Baseline Time after dosing (hr) Ref. Clinical study report of [CJ_APA_105] study
66 식전식후복용할수있어편리하다. On demand therapy 에적용할수있다 ) Arithmetic Mean Ref. Clinical study report of [CJ_APA_102] study
67 Simple formulation of K-CAB Tegoprazan 50 mg 10.0 mm x 6.8 mm Nexium 40 mg 16 mm x 8 mm Nexium 20 mg 14 mm x 7 mm Vonoprazan 20 mg 11.2 mm x 6.2 mm
68 Some more comments 성균관대학교의과대학삼성서울병원소화기내과이준행
69 Migrating motor complex (MMC) 를촉진 J Pharmacol Exp Ther. 2018
70 Stomach 에서의역할은?
71 Gastric ESD 의주된합병증은출혈 - ESD 당일아침 tegoprazan 을한번먹으면어떨까?
72 다른 P-CAB 과의비교
73 새롭고강력한위산분비억제제 Tegoprazan 의다양한 ( 잠재적 ) 적응증 Erosive esophagitis 의초치료및유지요법 Non-erosive reflux disease (NERD) 초치료유지요법 Refractory GERD 의일부 subtype 혹은경험적치료 Long-term treatment with on-demand method PPI 의 unmet needs 에해당하는경우 야간증상, 아침식전투약이어려운경우 Drug-drug interaction 이우려되는경우, PPI 의부작용 Rapid metabolizer, Clopidogrel 복용자 Helicobacter 제균치료
74 K-CAB: Fast, Strong and Long
GERD 치료최신지견및 P-CAB 의역할 성균관대학교의과대학삼성서울병원소화기내과이준행
GERD 치료최신지견및 P-CAB 의역할 성균관대학교의과대학삼성서울병원소화기내과이준행 P-CAB (Tegoprazan, K-CAB TM ) 국내제30호신약 (code명: RQ-4, CJ-12420) Potassium Competitive Acid Blocker 위산과위산분비억제제 성균관대학교의과대학삼성서울병원소화기내과이준행 William Beaumont 와
More informationGASTROINTESTINAL AND ANTIEMETIC DRUGS. Submitted by: Shaema M. Ali
GASTROINTESTINAL AND ANTIEMETIC DRUGS Submitted by: Shaema M. Ali GASTROINTESTINAL AND ANTIEMETIC DRUGS by: Shaema M. Ali There are four common medical conditions involving the GI system 1) peptic ulcers
More informationUnmet Needs in the Management of Gastroesophageal Reflux Disease
Unmet Needs in the Management of Gastroesophageal Reflux Disease Ronnie Fass MD Professor of Medicine Case Western Reserve University Chairman, Division of Gastroenterology and Hepatology Director, Esophageal
More informationProton Pump Inhibitors (PPIs) (Sherwood Employer Group)
Proton Pump Inhibitors (PPIs) (Sherwood Employer Group) BCBSKS will review Prior Authorization requests Prior Authorization Form: https://www.bcbsks.com/customerservice/forms/pdf/priorauth-6058ks-st-ippi.pdf
More informationHelicobacter 2008;13:1-6. Am J Gastroent 2007;102: Am J of Med 2004;117:31-35.
An Update on Helicobacter pylori and Its Treatment Trenika Mitchell, PharmD, BCPS Clinical Assistant Professor University of Kentucky College of Pharmacy October 18, 2008 Objectives Review the epidemiology
More informationCYP2C19-Proton Pump Inhibitors
CYP2C19-Proton Pump Inhibitors Cameron Thomas, Pharm.D. PGY2 Clinical Pharmacogenetics Resident St. Jude Children s Research Hospital February 1, 2018 Objectives: CYP2C19-PPI Implementation Review the
More informationOptimal Management of GERD with Dexlansoprazole - Extended plasma concentration and dosing flexibility with a dual delayed release PPI
Optimal Management of GERD with Dexlansoprazole - Extended plasma concentration and dosing flexibility with a dual delayed release PPI Jun Heng Lee, M.D. Samsung Medical Center, Sungkyunkwan University
More informationCommittee Approval Date: October 14, 2014 Next Review Date: October 2015
Medication Policy Manual Topic: esomeprazole-containing medications: - Nexium - Vimovo - esomeprazole strontium Policy No: dru039 Date of Origin: May 2001 Committee Approval Date: October 14, 2014 Next
More informationNEGATIVE ENDOSCOPY, What is the Diagnosis and Treatment?
NEGATIVE ENDOSCOPY, PPI REFRACTORY REFLUX: What is the Diagnosis and Treatment? Michael F. Vaezi, MD, PhD, MSc, FACG Professor of Medicine Clinical Director Division of Gastroenterology, Hepatology and
More informationDrug Class Monograph
Drug Class Monograph Class: Proton Pump Inhibitors Drugs: Aciphex Sprinkle (rabeprazole), Dexilant (dexlansoprazole), Lansoprazole, Nexium (esomeprazole capsule, esomeprazole granules), Omeprazole, Pantoprazole,
More informationProton Pump Inhibitors Drug Class Prior Authorization Protocol
Proton Pump Inhibitors Drug Class Prior Authorization Protocol Line of Business: Medi-Cal P&T Approval Date: November 15, 2017 Effective Date: January 1, 2018 This policy has been developed through review
More informationY. Sakurai*, Y. Mori*, H. Okamoto*, A. Nishimura*, E. Komura*, T. Araki* & M. Shiramoto
Alimentary Pharmacology and Therapeutics Acid-inhibitory effects of vonoprazan 2 mg compared with esomeprazole 2 mg or rabeprazole 1 mg in healthy adult male subjects - a randomised open-label cross-over
More information11/19/2012. Comparison between PPIs G CELL. Risk ratio (95% CI) Patient subgroup. gastrin. S-form of omeprazole. Acid sensitive. coated.
REGULATION OF GASTRIC ACID SECRETION Comparison between PPIs Omeprazole Lansoprazole Rabeprazole Pantoprazole Esomeprazole gastrin G CELL + Acid sensitive Yes T1/2 30-60 minutes Main elimination Enteric
More informationGERD: 2014 Dilemmas and Solutions. Ronnie Fass MD, FACP Professor of Medicine Case Western Reserve University
GERD: 2014 Dilemmas and Solutions Ronnie Fass MD, FACP Professor of Medicine Case Western Reserve University How to Maximize Your PPI Treatment? Improve compliance and adherance Fass R. Am J Gastroenterol.
More informationGERD DIAGNOSIS & TREATMENT DISCLOSURES 4/18/2018
GERD DIAGNOSIS & TREATMENT Subhash Chandra MBBS Assistant Professor CHI Health Clinic Gastroenterology Creighton University, School of Medicine April 28, 2018 DISCLOSURES None 1 OBJECTIVES Review update
More informationReview article: immediate-release proton-pump inhibitor therapy potential advantages
Aliment Pharmacol Ther 25; 22 (Suppl. 3): 25 3. Review article: immediate-release proton-pump inhibitor therapy potential advantages C. W. HOWDEN Division of Gastroenterology, Northwestern University Feinberg
More informationProton Pump Inhibitors. Description. Section: Prescription Drugs Effective Date: July 1, 2014
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.09.01 Subject: Proton Pump Inhibitors Page: 1 of 7 Last Review Date: June 12, 2014 Proton Pump Inhibitors
More informationRpts. GENERAL General Schedule (Code GE)
Pantoprazole 20mg Name, Restriction, Manner of administration and form Pantoprazole 20mg enteric tablet, 30 (8399C) Gastro-oesophageal reflux disease Name, Restriction, Manner of administration and form
More informationReview article: gastric acidity ) comparison of esomeprazole with other proton pump inhibitors
Aliment Pharmacol Ther 2003; 17 (Suppl. 1): 10 15. Review article: gastric acidity ) comparison of esomeprazole with other proton pump inhibitors J. G. HATLEBAKK Department of Medicine, Haukeland Sykehus,
More informationRpts. GENERAL General Schedule (Code GE) Program Prescriber type: Dental Medical Practitioners Nurse practitioners Optometrists Midwives
Esomeprazole 20mg Name, Restriction, Manner of esomeprazole 20 mg enteric tablet, 30 (8886Q) (029W) Gastric ulcer Peptic ulcer Treatment Phase: Initial treatment The therapy must be for initial treatment
More informationNexium 24HR. Tools and information for you and your pharmacy team NOW OTC FOR FREQUENT HEARTBURN. Consumer Healthcare Pfizer Inc.
NOW OTC FOR FREQUENT HEARTBURN w e N Nexium 24HR P H A R M A S S I S T K I T Tools and information for you and your pharmacy team 2014 Pfizer Inc. NXM041468 05/14 Q: What is the indication for Nexium 24HR
More informationProton Pump Inhibitors. Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.01 Subject: Proton Pump Inhibitors Page: 1 of 6 Last Review Date: June 24, 2015 Proton Pump Inhibitors
More informationIntragastric acidity during treatment with esomeprazole 40 mg twice daily or pantoprazole 40 mg twice daily a randomized, two-way crossover study
Aliment Pharmacol Ther 2005; 21: 963 967. doi: 10.1111/j.1365-2036.2005.02432.x Intragastric acidity during treatment with esomeprazole 40 mg twice daily or pantoprazole 40 mg twice daily a randomized,
More informationBIOMEDICAL REPORTS 6: , 2017
BIOMEDICAL REPORTS 6: 175-180, 2017 Efficacy of a potassium competitive acid blocker for improving symptoms in patients with reflux esophagitis, non erosive reflux disease, and functional dyspepsia DAISUKE
More informationOmeprazole 10mg. Name, Restriction, Manner of administration and form OMEPRAZOLE omeprazole 10 mg enteric tablet, 30 (8332M) Max. Qty.
Omeprazole 10mg Name, Restriction, Manner of administration and form omeprazole 10 mg enteric tablet, 30 (8332M) Gastro-oesophageal reflux disease Name, Restriction, Manner of administration and form omeprazole
More informationAppropriate Use of Proton Pump Inhibitors (PPIs) Anderson Mabour, Pharm.D., BCPS Clinical Pharmacy Specialist
Appropriate Use of Proton Pump Inhibitors (PPIs) Anderson Mabour, Pharm.D., BCPS Clinical Pharmacy Specialist Disclosures I have no actual or potential conflicts of interest to report in relation to this
More informationPrevpac Pylera Omeclamox-Pak
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.21 Subject: -Pak Page: 1 of 5 Last Review Date: September 20, 2018 -Pak Description (lansoprazole,
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: CP.CPA.209 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy for important
More informationPeptic ulcer disease Disorders of the esophagus
Peptic ulcer disease Disorders of the esophagus Peptic ulcer disease Burning epigastric pain Exacerbated by fasting Improved with meals Ulcer: disruption of mucosal integrity >5 mm in size, with depth
More informationHelicobacter pylori: Diagnosis, treatment and risks of untreated infection
Helicobacter pylori: Diagnosis, treatment and risks of untreated infection Klaus Mönkemüller Department of Gastroenterology, Hepatology und Infectius Diseases Otto-von-Guericke University, Magdeburg bb
More informationOriginal Policy Date
MP 2.04.38 Genetic Testing for Helicobacter pylori Treatment Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature search/12:2013 Return
More informationPPIs: Good or Bad? 1. Basics of PPIs. Gastric Acid Basics. Outline. Gastric Acid Basics. Proton Pump Inhibitors (PPI)
Outline Quick basics on Proton Pump Inhibitors (PPIs) PPIs: Good or Bad? What are potential risks of PPI therapy? How to approach your patients American Gastroenterology Association (AGA) recommendations
More informationPthaigastro.org. Evolution of antisecretory agents. History. Antacids and anticholinergic drugs
Evolution of antisecretory agents uthapong Ukarapol, MD. Division of Gastroenterology Chiang Mai University istory 1823- Prout discovered gastric hydrochloric acid 1875- eidenhain and 1893- Golgi identified
More informationProton Pump Inhibitors
Market DC Proton Pump Inhibitors Override(s) Prior Authorization Quantity Limit** Approval Duration Preferred PPI: No Prior Authorization required Preferred PPI quantity override: Lifetime Non-Preferred
More informationQUICK QUERIES. Topical Questions, Sound Answers
QUICK QUERIES Topical Questions, Sound Answers Dyspepsia: An Evidence-Based Approach Alan B. R. Thomson, MD, PhD, FRCPC, FACP, FACG Presented at the University of Alberta s Medical Grand Rounds, University
More information헬리코박터제균요법에있어서 CYP2C19 유전형이판토프라졸과라베프라졸포함치료법에미치는영향. Introduction 울산대학교의과대학서울아산병원소화기내과
The Korean Journal of Helicobacter and Upper Gastrointestinal Research Vol. 8, No. 1, 15-19, July 2008 Influence of CYP2C19 Polymorphism on Eradication of Helicobacter pylori: Comparison between Pantoprazole
More informationEradication of H. pylori Infection in Patients Allergic to Penicillin Using Triple Therapy with a PPI, Metronidazole and Sitafloxacin
CASE REPORT Eradication of H. pylori Infection in Patients Allergic to Penicillin Using Triple Therapy with a PPI, Metronidazole and Sitafloxacin Takahisa Furuta 1, Mitsushige Sugimoto 2, Mihoko Yamade
More informationPharmacy Coverage Guidelines are subject to change as new information becomes available.
PROTON PUMP INHIBITORS, NON-PREFERRED FORMS: ACIPHEX (rabeprazole sodium EC) oral tablet ACIPHEX SPRINKLE (rabeprazole sodium DR) oral capsule ESOMEPRAZOLE STRONTIUM (esomeprazole strontium DR) oral capsule
More informationChapter 63 Drugs Used in the Treatment of Gastrointestinal Diseases
Chapter 63 Drugs Used in the Treatment of Gastrointestinal Diseases p1009 DRUGS USED IN ACID-PEPTIC DISEASES 1. classification of drugs 2. agents that reduce intragastric acidity Antacids,H 2 antagonists,proton
More informationRefractory GERD. Kenneth R. DeVault, MD, FACG President American College of Gastroenterology Chair Department of Medicine Mayo Clinic Florida
Refractory GERD Kenneth R. DeVault, MD, FACG President American College of Gastroenterology Chair Department of Medicine Mayo Clinic Florida Objectives Define the terminology associated with refractory
More informationCopy right protected Page 1
DRUGS USED IN ULCERS AND GIT DISORDERS A peptic ulcer, also known as PUD or peptic ulcer disease is an ulcer of an area of the gastrointestinal tract that is usually acidic and thus extremely painful.
More informationNational Digestive Diseases Information Clearinghouse
Gastritis National Digestive Diseases Information Clearinghouse U.S. Department of Health and Human Services NATIONAL INSTITUTES OF HEALTH What is gastritis? Gastritis is a condition in which the stomach
More informationMANAGEMENT OF DYSPEPSIA AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT OF DYSPEPSIA AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) Routine endoscopic investigation of patients of any age, presenting with dyspepsia
More informationGI Pharmacology. Dr. Alia Shatanawi 5/4/2018
GI Pharmacology Dr. Alia Shatanawi 5/4/2018 Drugs Used in Gastrointestinal Diseases Drugs used in Peptic Ulcer Diseases. Drugs Stimulating Gastrointestinal Motility &Laxatives. Antidiarrheal Agents. Drugs
More informationDisclosures. Proton Pump Inhibitors Deprescribing? Deprescribing PPI Objectives. Deprescribing. Proton Pump Inhibitors (PPI) 5/28/2018.
Proton Pump Inhibitors Deprescribing? None Disclosures Chad Burski, MD Assistant Professor of Medicine UAB Gastroenterology Deprescribing PPI Objectives AR Why? Who? How? The mechanism of action of Proton
More informationOSPAP Programme. Gastrointestinal Drugs. Dr. Adrian Moore Dale
PAP Programme Dr. Adrian Moore Dale 1.03 Adrian.Moore@sunderland.ac.uk 0191 5152554 lide 1 of 26 PAP MPM14 Acid-Related Pathophysiology The stomach secretes: ydrochloric acid (Cl) aids digestion and also
More informationGastro-oesophageal reflux disease and peptic ulcer disease. By: Dr. Singanamala Suman Assistant Professor Department of Pharm.D
Gastro-oesophageal reflux disease and peptic ulcer disease By: Dr. Singanamala Suman Assistant Professor Department of Pharm.D Gastro-oesophageal reflux disease and peptic ulcer disease Learning objectives:
More informationCOMPARISON OF ONCE-A-DAY VERSUS TWICE-A-DAY CLARITHROMYCIN IN TRIPLE THERAPY FOR HELICOBACTER PYLORI ERADICATION
Phil J Gastroenterol 2006; 2: 25-29 COMPARISON OF ONCE-A-DAY VERSUS TWICE-A-DAY CLARITHROMYCIN IN TRIPLE THERAPY FOR HELICOBACTER PYLORI ERADICATION Marianne P Collado, Ma Fatima P Calida, Peter P Sy,
More informationPolicy Evaluation: Proton Pump Inhibitors (PPIs)
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationGastroesophageal Reflux Disease in Time Covering Eradication for All Patients Infected with Helicobacter pylori in Japan
Review Published online: January 14, 216 Gastroesophageal Reflux Disease in Time Covering Eradication for All Patients Infected with Helicobacter pylori in Mitsushige Sugimoto a, c Takahiro Uotani c, e
More informationReflux of gastric contents, particularly acid, into the esophagus
Heartburn Reflux of gastric contents, particularly acid, into the esophagus Patient assessment with GERD 1-signs and symptoms The hallmark of typical symptom of GERD is heartburn (restrosternal),acid regurgitation,
More informationRefractory GERD : case presentation and discussion
Refractory GERD : case presentation and discussion Ping-Huei Tseng National Taiwan University Hospital May 19, 2018 How effective is PPI based on EGD? With GERD symptom 75% erosive 25% NERD Endoscopy 81%
More informationHigh use of maintenance therapy after triple therapy regimes in Ireland
High use of maintenance therapy after triple therapy regimes in Ireland K Bennett, H O Connor, M Barry, C O Morain, J Feely Department of Pharmacology & Therapeutics Department of Gastroenterology Trinity
More informationA. Incorrect! Histamine is a secretagogue for stomach acid, but this is not the only correct answer.
Pharmacology - Problem Drill 21: Drugs Used To Treat GI Disorders No. 1 of 10 1. Endogenous secretagogues for stomach acid include: #01 (A) Histamine (B) Gastrin (C) PGE1 (D) A and B (E) A, B and C Histamine
More informationDeveloping Evidence-Based Best Practices for the Prescribing and Use of Proton Pump Inhibitors in Canada
Developing Evidence-Based Best Practices for the Prescribing and Use of Proton Pump Inhibitors in Canada Presented by: Sumeet R. Singh, COMPUS April 4, 2006 Background COMPUS Objective: To identify and
More informationBurning Issues in Gastroesophageal Reflux Disease (GERD)
3:45 4:45pm Burning Issues in GERD SPEAKER Prateek Sharma, MD, FACG, FACP Presenter Disclosure Information The following relationships exist related to this presentation: Prateek Sharma, MD, FACG, FACP,
More informationEMILOK Global. (omeprazole) Composition: Each capsule contains 20 mg omeprazole as enteric-coated
EMILOK Global (omeprazole) Composition: Each capsule contains 20 mg omeprazole as enteric-coated granules. Properties: Emilok (omeprazole) belongs to the group of proton pump inhibitors, inhibits both
More informationDexlansoprazole MR in the Management of Gastroesophageal Reflux Disease
Clinical Medicine: Therapeutics R e v i e w Open Access Full open access to this and thousands of other papers at http://www.la-press.com. Dexlansoprazole MR in the Management of Gastroesophageal Reflux
More informationAstraZeneca and Daiichi Sankyo Launch Proton Pump Inhibitor Nexium 10 mg and 20 mg Granules for Suspension, Sachet, in Japan
AstraZeneca K.K. Daiichi Sankyo Co., Ltd. AstraZeneca and Daiichi Sankyo Launch Proton Pump Inhibitor Nexium 10 mg and 20 mg Granules for Suspension, Sachet, in Japan Osaka and Tokyo, Japan, April 18,
More informationReview article: pharmacology of esomeprazole and comparisons with omeprazole
Aliment Pharmacol Ther 2003; 17 (Suppl. 1): 5 9. Review article: pharmacology of esomeprazole and comparisons with omeprazole J. DENT Department of Gastroenterology, Hepatology and General Medicine, Royal
More informationHold the Wrap! There is so much more to be done!
Hold the Wrap! There is so much more to be done! (Well, a few things that can be done.) (Well, not all that much, really ) (But Blair has never killed anyone with a PPI!) Nicholas Shaheen, MD, MPH Center
More informationpissn: eissn: https://doi.org/ /jnm18001 Journal of Neurogastroenterology and Motility
JNM J Neurogastroenterol Motil, Vol. 24 No. 2 April, 2018 pissn: 2093-0879 eissn: 2093-0887 https://doi.org/10.5056/jnm18001 Review Advantages and Disadvantages of Long-term Proton Pump Inhibitor Use Yoshikazu
More informationDisclosures. Co-founder and Chief Science Officer, TechLab
H. pylori testing Disclosures Co-founder and Chief Science Officer, TechLab Learning Objectives Evaluate the appropriate testing methodology by balancing performance, economics, and workflow. Discuss the
More informationDrug Class Review on Proton Pump Inhibitors
Drug Class Review on Proton Pump Inhibitors Final Report Update 4 July 2006 Original Report Date: November 2002 Update 1 Report Date: April 2003 Update 2 Report Date: April 2004 Update 3 Report Date: May
More informationGI Pharmacology. Dr. Alia Shatanawi 5/4/2018
GI Pharmacology Dr. Alia Shatanawi 5/4/2018 Z Gastroenterol. 1983 Mar;21 Suppl:111-6. [Effect of antacids on intestinal motility]. [Article in German] Wienbeck M, Erckenbrecht J, Strohmeyer G. Abstract
More informationPEPTIC ULCER DISEASE JOHN R SALTZMAN, MD. Director of Endoscopy Brigham and Women s Hospital Professor of Medicine Harvard Medical School
PEPTIC ULCER DISEASE JOHN R SALTZMAN, MD Director of Endoscopy Brigham and Women s Hospital Professor of Medicine Harvard Medical School No disclosures Disclosures Overview Causes of peptic ulcer disease
More information- Ali Yaghi. - Sara Yaghi. - Alia Shatnawi. 1 P a g e
-2 - Ali Yaghi - Sara Yaghi - Alia Shatnawi 1 P a g e We ended the previous lecture with H2 receptor antagonists, which work by selectively inhibiting H2 receptors. They are widely used to treat: 1- GERD,
More informationCOMPUS OPTIMAL THERAPY REPORT. Supporting Informed Decisions. À l appui des décisions éclairées
OPTIMAL THERAPY REPORT COMPUS Volume 1, Issue 6 March 2007 Gap Analysis Report for the Prescribing and Use of Proton Pump Inhibitors (PPIs) Supporting Informed Decisions À l appui des décisions éclairées
More informationEffects of rabeprazole, lansoprazole and omeprazole on intragastric ph in CYP2C19 extensive metabolizers
Aliment Pharmacol Ther 2002; 16: 1811 1817. doi:10.1046/j.0269-2813.2002.01348.x Effects of rabeprazole, lansoprazole and omeprazole on intragastric ph in CYP2C19 extensive metabolizers T. SAITOH*, Y.
More informationPROTON PUMP INHIBITOR AND CLOPIDOGREL INTERACTION: Am J Gastroenterol Jan;105(1): Epub 2009 Nov 10.
PROTON PUMP INHIBITOR AND CLOPIDOGREL INTERACTION: FACT OR FICTION? 本檔僅供內部教學使用檔案內所使用之照片之版權仍屬於原期刊公開使用時, 須獲得原期刊之同意授權 Am J Gastroenterol. 2010 Jan;105(1):34-41. Epub 2009 Nov 10. Introduction Current consensus
More information1. The proposed strength, quantity, dosage form, dose and route of administration of the medicine including indication
Investigation 10mg 1. The proposed strength, quantity, dosage form, dose and route of administration of the medicine including indication Blister packs of 14 Solid dose form for oral administration. It
More informationPRESCRIBING SUPPORT TEAM AUDIT: PROTON PUMP INHIBITOR PRESCRIBING REVIEW
PRESCRIBING SUPPORT TEAM AUDIT: PROTON PUMP INHIBITOR PRESCRIBING REVIEW DATE OF AUTHORISATION: AUTHORISING GP: PRESCRIBING SUPPORT TECHNICIAN: SUMMARY Dyspepsia refers to a broad range of symptoms related
More informationEsomeprazole versus omeprazole for the eradication of Helicobacter pylori infection
International Journal of Community Medicine and Public Health Ageeli R et al. Int J Community Med Public Health. 2018 Jul;5(7):2686-2691 http://www.ijcmph.com pissn 2394-6032 eissn 2394-6040 Original Research
More informationVonoprazan for treatment of gastroesophageal reflux: pharmacodynamic and pharmacokinetic considerations
Expert Opinion on Drug Metabolism & Toxicology ISSN: 1742-5255 (Print) 1744-7607 (Online) Journal homepage: http://www.tandfonline.com/loi/iemt20 Vonoprazan for treatment of gastroesophageal reflux: pharmacodynamic
More informationDisclosures. GI Motility Disorders. Gastrointestinal Motility Disorders & Irritable Bowel Syndrome
Gastrointestinal Motility Disorders & Irritable Bowel Syndrome None Disclosures Jasmine Zia, MD Acting Assistant Professor Division of Gastroenterology, University of Washington 6 th Asian Health Symposium
More informationSystematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease where next?
Aliment Pharmacol Ther 2005; 22: 79 94. doi: 10.1111/j.1365-2036.2005.02531.x Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease where next? R. FASS, M. SHAPIRO, R. DEKEL
More informationIJPRD, 2013; Vol 4(12): February-2013 ( ) International Standard Serial Number
IJPRD, 2013; Vol 4(12): February-2013 (037 055) International Standard Serial Number 0974 9446 --------------------------------------------------------------------------------------------------------------------------------------------------
More informationAlimentary Pharmacology & Therapeutics SUMMARY
Alimentary Pharmacology & Therapeutics Comparison of the effects of immediate-release omeprazole oral suspension, delayed-release lansoprazole capsules and delayedrelease esomeprazole capsules on nocturnal
More informationCOMPUS OPTIMAL THERAPY REPORT. Supporting Informed Decisions. À l appui des décisions éclairées. Proton Pump Inhibitor Project Overview: Summaries
OPTIMAL THERAPY REPORT COMPUS Volume 1, Issue 1 March 2007 Proton Pump Inhibitor Project Overview: Summaries Supporting Informed Decisions À l appui des décisions éclairées This Executive Summary is based
More informationand 2 Negma-Lerads, Toussus-le-Noble, Magny-Les-Hameaux Cedex, France INTRODUCTION
American Journal of Gastroenterology ISSN 0002-9270 C 2005 by Am. Coll. of Gastroenterology doi: 10.1111/j.1572-0241.2005.41956.x Published by Blackwell Publishing Effect on Intragastric ph of a PPI with
More informationORIGINAL ARTICLE. Abstract
ORIGINAL ARTICLE Characteristics of Refractory Gastroesophageal Reflux Disease (GERD) Symptoms Is Switching Proton Pump Inhibitors Based on the Patient s CYP2C19 Genotype an Effective Management Strategy?
More informationManagement of Dyspepsia
MPharm Programme Management of Dyspepsia Slide 1 of 28 Learning Objectives Understand the principles and wider implications underpinning evidence based therapeutics in the key clinical specialities Objectively
More informationNew Therapeutic Options in the Treatment of GERD and Other Acid-Peptic Disorders
...SYMPOSIUM PROCEEDINGS... New Therapeutic Options in the Treatment of GERD and Other Acid-Peptic Disorders Based on a presentation by Duane D. Webb, MD, FACG Presentation Summary Gastroesophageal reflux
More informationA model of healing of Los Angeles grades C and D reflux oesophagitis: is there an optimal time of acid suppression for maximal healing?
Alimentary Pharmacology and Therapeutics A model of healing of Los Angeles grades C and D reflux oesophagitis: is there an optimal time of acid suppression for maximal healing? P. O. Katz*, D. A. Johnson
More informationEffective Health Care
Effective Health Care Comparative Effectiveness of Management Strategies for Gastroesophageal Reflux Disease Executive Summary Background Gastroesophageal reflux disease (GERD), defined as weekly heartburn
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: helicobacter_pylori_testing 01/01/2019 N/A 01/01/2020 01/01/2019 Policy Effective April 1, 2019 Description
More informationThis PDF is available for free download from a site hosted by Medknow Publications
Research Paper www.ijpsonline.com Inter-Individual Variation in Pharmacokinetics of Proton Pump Inhibitors in Healthy Indian Males SHUBHA RANI AND HARISH PADH* B. V. Patel Pharmaceutical Education and
More informationProton Pump Inhibitors- Questions & Controversies. Farah Kablaoui, PharmD, BCPS, BCCCP
Proton Pump Inhibitors- Questions & Controversies Farah Kablaoui, PharmD, BCPS, BCCCP Disclosure Information Proton Pump Inhibitors: Questions & Controversies Farah Kablaoui I have no financial relationship
More informationEpidemiology of Peptic Ulcer Disease
Epidemiology of Peptic Ulcer Disease Introduction Peptic Ulcer Disease (PUD) is disruption of the mucosal integrity of the stomach and/or duodenum leading to a local defect or excavation due to active
More informationPhiladelphia College of Osteopathic Medicine. Shawn P. Mahoney Philadelphia College of Osteopathic Medicine,
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2011 Is Esomeprazole (Nexium) More Effective
More informationOVERALL SUMMARY OF THE SCIENTIFIC EVALUATION OF LOSEC AND ASSOCIATED NAMES (SEE ANNEX I)
ANNEX II SCIENTIFIC CONCLUSIONS AND GROUNDS FOR AMENDMENT OF THE SUMMARY OF PRODUCT CHARACTERISTICS, LABELLING AND PACKAGE LEAFLET PRESENTED BY THE EMEA 21 SCIENTIFIC CONCLUSIONS OVERALL SUMMARY OF THE
More informationThe Association and Clinical Implications of Gastroesophgeal Reflux Disease and H. pylori
The Association and Clinical Implications of Gastroesophgeal Reflux Disease and H. pylori Maxwell M. Chait The relationship between GERD and H. pylori is complex and negatively associated with important
More informationDERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT OF DYSPEPSIA
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT OF DYSPEPSIA o Patients of any age with ALARM signs should be referred through the 2-week referral system o Routine endoscopic investigation
More informationDrugs Affecting the Gastrointestinal System. Antacids, Constipation, Increasing gastrointestinal motility
Drugs Affecting the Gastrointestinal System Antacids, Constipation, Increasing gastrointestinal motility Cells of the Gastric Gland parietal cells: produce & secrete HCl primary site of action for many
More informationOral esomeprazole vs. intravenous pantoprazole: a comparison of the effect on intragastric ph in healthy subjects
Aliment Pharmacol Ther 2003; 18: 705 711. doi: 10.1046/j.1365-2036.2003.01743.x Oral esomeprazole vs. intravenous pantoprazole: a comparison of the effect on intragastric in healthy subjects D. ARMSTRONG*,
More informationGASTROINTESTINAL SYSTEM MANAGEMENT OF DYSPEPSIA
GASTROINTESTINAL SYSTEM MANAGEMENT OF DYSPEPSIA MANAGEMENT Dyspepsia refers to a spectrum of usually intermittent upper gastrointestinal symptoms, including epigastric pain and heartburn. For the majority
More informationTECHNOLOGY OVERVIEW: PHARMACEUTICALS
TECHNOLOGY OVERVIEW: PHARMACEUTICALS ISSUE 3.1 JUNE 1996 PHARMACEUTICAL MANAGEMENT OF PEPTIC ULCER DISEASE prepared by Ms. Christine Perras, BSc Phm Pharmaceutical Associate, CCOHTA and Dr. Nicolaas Otten,
More informationClass Update: Proton Pump Inhibitors and Histamine 2 Receptor Antagonists
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More information